OSTX — OS Therapies Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1795091 ·
Last close
$1.72
Market Cap
$76.61M
52W High
$2.20
52W Low
$1.16
ADV30
679,852
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,167,938 | -10,396,831 | 7,299,236 | 917,552 | 18,123,474 |
| Dec 2025 | 0 | — | -11,987,892 | -13,460,833 | 6,839,534 | 269,830 | 12,935,165 |
| Sep 2025 | 0 | — | -6,879,595 | -6,879,530 | 8,953,251 | 1,876,626 | 5,316,056 |
| Jun 2025 | 0 | — | -4,838,728 | -4,536,622 | 10,310,475 | 2,802,013 | 5,366,828 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,360,230
Investing CF
$-292,787
Financing CF
$13,599,562
CapEx
$-466,423
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.85
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,583,050
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,198,472
Pretax Income TTM
$-35,273,816
Interest Exp TTM
$75,344
Analysts
4
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,705,701 | -28,753,844 | 6,839,534 | 12,935,165 | — | -14,238,576 |
| Dec 2024 | 0 | -6,813,846 | -8,882,938 | 5,538,797 | 8,805,335 | — | -7,282,295 |
| Dec 2023 | 0 | -4,342,645 | -7,791,582 | 798,082 | 24,814,297 | — | -3,006,967 |
| Dec 2022 | 0 | -4,446,299 | -6,254,685 | 509,105 | 18,066,333 | — | -3,792,580 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.21
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BHST | BIOHARVEST SCIENCES INC. | $76.62M | $3.38 | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $76.49M | $0.40 | — |
| ACET | Adicet Bio, Inc. | $75.81M | $8.11 | — |
| ANVS | Annovis Bio, Inc. | $75.72M | $1.78 | — |
| ELTX | Elicio Therapeutics, Inc. | $77.87M | $4.08 | — |
News headlines (Yahoo Finance, 1h cache)
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
2026-06-08 10:00 · Yahoo
OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma
2026-06-02 10:25 · Yahoo
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
2026-06-02 10:00 · Yahoo
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
2026-05-29 11:20 · Yahoo
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
2026-05-26 11:40 · Yahoo
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
2026-05-18 10:30 · Yahoo
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
2026-05-15 20:05 · Yahoo
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
2026-05-14 11:30 · Yahoo
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
2026-05-12 18:35 · Yahoo
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Oste
2026-04-30 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.